Literature DB >> 2449544

Human T-cell response to myelin basic protein in multiple sclerosis patients and healthy subjects.

E Tournier-Lasserve1, G A Hashim, M A Bach.   

Abstract

In order to explore the T-cell repertoire to myelin basic protein (BP) of both multiple sclerosis (MS) patients and healthy subjects (HS), we raised BP reactive T-cell lines from blood mononuclear cells of eight MS patients and five HS. These lines were triggered in vitro by human BP. When analyzing their patterns of recognition of human BP versus heterologous BP, we could observe differences between healthy subjects and MS patients. Whereas T-cell lines from healthy subjects developed a response to heterologous BP, which was in most cases equal or higher than that elicited by human BP, T-cell lines from most MS patients displayed a low response, or no response at all, to one or several of the heterologous BP tested. A low response to bovine BP was only observed in active cases, whereas decreased responses to rat and/or monkey BP were observed both during remission and during active disease. This may indicate that T-cell repertoire to BP in MS patients differs from that of healthy subjects. BP-reactive T-cell clones were obtained by limiting dilution from two healthy subject lines. Their pattern of response to heterologous BP as compared to human BP suggest that T-cells from the same individual can recognize different BP epitopes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449544     DOI: 10.1002/jnr.490190120

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

1.  Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma.

Authors:  T Olsson; W W Zhi; B Höjeberg; V Kostulas; Y P Jiang; G Anderson; H P Ekre; H Link
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

2.  Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.

Authors:  M Pette; K Fujita; D Wilkinson; D M Altmann; J Trowsdale; G Giegerich; A Hinkkanen; J T Epplen; L Kappos; H Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

Authors:  N Kerlero de Rosbo; R Milo; M B Lees; D Burger; C C Bernard; A Ben-Nun
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

4.  Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non-arthritic controls.

Authors:  N J Goodstone; M C Doran; R N Hobbs; R C Butler; J J Dixey; B A Ashton
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

Review 5.  The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy.

Authors:  Peter O Behan; Abhijit Chaudhuri
Journal:  Inflammopharmacology       Date:  2010-09-24       Impact factor: 5.093

6.  Multi-HLA class II tetramer analyses of citrulline-reactive T cells and early treatment response in rheumatoid arthritis.

Authors:  Christina Gerstner; Sara Turcinov; Aase H Hensvold; Karine Chemin; Hannes Uchtenhagen; Tamara H Ramwadhdoebe; Anatoly Dubnovitsky; Genadiy Kozhukh; Lars Rönnblom; William W Kwok; Adnane Achour; Anca I Catrina; Lisa G M van Baarsen; Vivianne Malmström
Journal:  BMC Immunol       Date:  2020-05-18       Impact factor: 3.615

7.  Investigation of the role of delayed-type-hypersensitivity responses to myelin in the pathogenesis of Theiler's virus-induced demyelinating disease.

Authors:  P Borrow; C J Welsh; P Tonks; D Dean; W F Blakemore; A A Nash
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

Review 8.  Polyomavirus models of brain infection and the pathogenesis of multiple sclerosis.

Authors:  G L Stoner
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.